All episodes
Episode 243: ASCO 2023 TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide
Episode 242: ASCO 2023 THOR study - erdafitinib vs chemo in bladder cancer
Episode 241: Statistics for clinical trials
Episode 240: Preview of GU Cancer at ASCO 2023
Episode 239: The STAMPEDE trial
Episode 238: Paper of the month: Biomarkers for neoadjuvant PD(L)1 therapy
Episode 237: 2023 AUA Highlights
Episode 236: ODAC for olaparib
Episode 235: Danny Heng and the IMDC classification in renal cancer
Episode 234: Amar Kishan, MD, on Neoadjuvant or Adjuvant Radiotherapy for Prostate Cancer
Episode 233: Destaques da 14ª reunião internacional brasileira de câncer urológico
Episode 232: Belzutifan in early and late renal cancer
Episode 231: Ursula Vogl, MD in the Rising Star Series
Episode 230: FGFR Inhibition in NMIBC With Sia Daneshmand
Episode 229: Kala Sridhar, MD on PET in Early Bladder Cancer
Episode 228: Karine Tawagi, MD in the Rising Star Series
Episode 227: 2023 ASCO GU Bladder Highlights and Paper of the Month with Michiel Van der Heijden
Episode 226: 2023 ASCO GU Prostate and RCC Highlights With Dan George
Episode 225: ASCO GU 2023: Brian Shuch, MD discusses the ZIRCON Phase III Study of girentuximab PET/CT imaging in RCC
Episode 224: ASCO GU 2023: discussing miR371 for Germ Cell Tumors with Christian Kollmannsberger
Episode 223: ASCO GU 2023: Discussing KEYNOTE-057 with Andrea Necchi, MD
Episode 222: ASCO GU 2023: New Data From IMvigor130 with Enrique Grande, MD
Episode 221: ASCO GU 2023: Matt Galsky, MD Gives an Update on the CheckMate 274 Trial
Episode 220: ASCO GU 2023: Discussing PARPi for CRPC with Michael Morris, MD
Episode 219: ASCO GU 2023: Neeraj Agarwal, MD, FASCO Discusses the TALAPRO-2 study
Episode 218: Discussing The Cost of Cancer Drugs With Daniel Goldstein, MD
Episode 217: Rising Star: Vadim Koshkin and ADCs
Episode 216: ADCs in Bladder Cancer With Petros Grivas, MD, PhD
Episode 215: Resumen cáncer de próstata y vejiga reunión Canarias
Episode 214: Resumen de la reunión en las Islas Canarias sobre cáncer renal
Episode 213: IL-15RaFc superagonist in NMIBC
Episode 212: What's coming in GU Cancers in 2023
Episode 211: CAR-T cell therapy in RCC
Episode 210: Christmas Prostate Cancer Debate - olaparib and abiraterone in selected or unselected patients
Episode 209: Christmas Bladder Cancer Debate - Cisplatin vs carboplatin in bladder cancer
Episode 208: Christmas Kidney Cancer Debate - Ipilimumab in renal cancer
Episode 207: Editorial on COSMIC-313
Episode 206: Dan Shapiro in the Rising Star series
Episode 205: Paper of the Month - Nab-paclitaxel and pembrolizumab in bladder cancer
Episode 204: Scott Haake in the Rising Star series
Episode 203: Renee Saliby in the Rising Star series
Episode 202: The Uromigos Paper of the Month - Docetaxel with or without continuous enza in CRPC
Episode 201: PARPi in CRPC
Episode 200: Chromophobe renal cancer
Episode 199: The Uromigos Paper of the Month - FGFR inhibition in bladder cancer
Episode 198: The RADICALS trial in prostate cancer
Episode 197: The Uromigos Nashville 2022
Episode 196: The COSMIC-313 Trial cabo/ipi/nivo in 1st line renal cancer
Episode 195 ESMO 2022: EV Pembrolizumab in 1st line bladder cancer
Episode 194 ESMO 2022: Pegylated il-2 + nivolumab in renal cancer
Episode 193 ESMO 2022: PRESTO - a phase III trial of androgen annihilation in biochemically relapsed prostate cancer
Episode 192 ESMO 2022: Summary of ESMO Adjuvant RCC Trials
Episode 191 ESMO 2022: PROSPER study of neoadjuvant nivolumab in RCC
Episode 190: ESMO 2022 Preview
Episode 189: The Uromigos Paper of the Month - Robotic vs open cystectomy
Episode 188: The 1st Uromigos Live and Unplugged face-to-face meeting
Episode 187: Cora Sternberg - The Uromigos Legends Series
Episode 186: Bernard Escudier - The Uromigos Legends Series
Episode 185: The Uromigos Paper of the Month - ctDNA in prostate cancer
Episode 184: Active surveillance in prostate cancer and the seeds of doubt
Episode 183: Oliver Sartor - The Uromigos Legends Series
Episode 182: ASCO Kidney Cancer Guidelines
Episode 181: Relapsed Germ Cell Tumours
Episode 180: Enzalutamide vs active surveillance in early prostate cancer
Episode 179: PSMA PET for Lutetium-177 in prostate cancer
Episode 178: ASCO 2022: Germline variants in men of African descent with prostate cancer
Episode 177: ASCO 2022: ENZAMET survival update
Episode 176: ASCO 2022: HER-2 ADCs in Bladder Cancer
Episode 175: ASCO 2022: Targeting the microbiome in renal cancer
Episode 174: ASCO 2022: Cell free DNA as a biomarker in bladder cancer
Episode 173: ASCO 2022: The Atlantis Trial - maintenance cabozantinib in bladder cancer
Episode 172: ASCO 2022: Adjuvant everolimus in renal cancer
Episode 171: Antibody drug conjugates in bladder cancer: managing adverse effects
Episode 170: APCCC Meeting Summary
Episode 169: The Uromigos Paper of the Month - Novel neoadjuvant approaches in UC
Episode 168: Mechanisms of response to PD1 therapy in renal cancer
Episode 167: Highlights from EIKCS oral session
Episode 166: Prostate cancer debate: doublet vs triplet first line therapy
Episode 165: Paper of the Month - ENZAMET quality of life data
Episode 164: Paper of the Month - what can we learn from R3 ipilimumab/nivolumab in gastric cancer
Episode 163: The Uromigos Debate - Treatment of favorable risk renal cancer
Episode 162: Debate - Adjuvant nivolumab for bladder cancer
Episode 161: Platinum eligibility in urothelial cancer
Episode 160: APCCC - PMSA PET as a diagnostic
Episode 159: ASCO GU 2022 Adjuvant and neoadjuvant therapy in renal cancer
Episode 158: ASCO GU 2022 PROpel Phase III olaparib and abiraterone in renal cancer
Episode 156: ASCO GU 2022 1st line olaparib and durvalumab in bladder cancer
Episode 157: ASCO GU 2022 Sasatuzimab and pembrolizumab in bladder cancer
Episode 154: ASCO GU 2022 MAGNITUDE trial of niraparib and abiraterone in metastatic CRPC
Episode 155: ASCO GU 2022 ARASENS trial of darolutamide plus chemo vs chemo alone in hormone sensitive advanced prostate cancer
Episode 153: Overview of PARP inhibition in prostate cancer
Episode 152: The Uromigos Paper of the Month - Zr-Pembrolizumab PET Imaging
Episode 151: Bladder Cancer ESMO Guidelines update
Episode 150: Comparing the quality of life data in renal trials
Episode 149: Treatment-free survival for ipilimumab and nivolumab
Episode 148: The Uromigos Paper of the Month - Stereotactic radiotherapy for advanced renal cancer
Episode 147: Renal Cancer Christmas Special
Episode 146: Bladder Cancer Christmas Special
Episode 145: Prostate Cancer Christmas Special
Episode 144: Pembrolizumab for bladder cancer